Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker-Guided CAR-T Therapy (CD19 or BCMA) in Refractory SLE
NCT07523542Phase 2Recruiting
- Sponsor
- Biotech Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of autologous anti-CD19 CAR-T cells in systemic lupus erythematosus (SLE), lupus nephritis (LN), sponsored by Biotech Pharmaceutical. Started Mar 2026; status: recruiting.
02
Drugs
autologous anti-CD19 CAR-T cells
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)
Beyond the preview
Go deeper on NCT07523542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07523542.